Can artificial intelligence identify effective COVID‐19 therapies?

In this issue of EMBO Molecular Medicine, Stebbing et al (2020b) validate an artificial intelligence‐assisted prediction that a drug used to treat rheumatoid arthritis could be a potent weapon against COVID‐19. Using liver organoids infected with SARS‐CoV‐2, they confirm dual antiviral and anti‐infl...

Descripción completa

Detalles Bibliográficos
Autores principales: Schultz, Michael B, Vera, Daniel, Sinclair, David A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
News & Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361072/
https://www.ncbi.nlm.nih.gov/pubmed/32569446
http://dx.doi.org/10.15252/emmm.202012817
_version_ 1783559337632858112
author Schultz, Michael B
Vera, Daniel
Sinclair, David A
author_facet Schultz, Michael B
Vera, Daniel
Sinclair, David A
author_sort Schultz, Michael B
collection PubMed
description In this issue of EMBO Molecular Medicine, Stebbing et al (2020b) validate an artificial intelligence‐assisted prediction that a drug used to treat rheumatoid arthritis could be a potent weapon against COVID‐19. Using liver organoids infected with SARS‐CoV‐2, they confirm dual antiviral and anti‐inflammatory activities and show that its administration in four COVID‐19 patients is correlated with disease improvement, paving the way for more rigorous placebo‐controlled trials.
format Online
Article
Text
id pubmed-7361072
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-73610722020-07-15 Can artificial intelligence identify effective COVID‐19 therapies? Schultz, Michael B Vera, Daniel Sinclair, David A EMBO Mol Med News & Views In this issue of EMBO Molecular Medicine, Stebbing et al (2020b) validate an artificial intelligence‐assisted prediction that a drug used to treat rheumatoid arthritis could be a potent weapon against COVID‐19. Using liver organoids infected with SARS‐CoV‐2, they confirm dual antiviral and anti‐inflammatory activities and show that its administration in four COVID‐19 patients is correlated with disease improvement, paving the way for more rigorous placebo‐controlled trials. John Wiley and Sons Inc. 2020-07-07 2020-08-07 /pmc/articles/PMC7361072/ /pubmed/32569446 http://dx.doi.org/10.15252/emmm.202012817 Text en © 2020 The Authors. Published under the terms of the CC BY 4.0 license This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle News & Views
Schultz, Michael B
Vera, Daniel
Sinclair, David A
Can artificial intelligence identify effective COVID‐19 therapies?
title Can artificial intelligence identify effective COVID‐19 therapies?
title_full Can artificial intelligence identify effective COVID‐19 therapies?
title_fullStr Can artificial intelligence identify effective COVID‐19 therapies?
title_full_unstemmed Can artificial intelligence identify effective COVID‐19 therapies?
title_short Can artificial intelligence identify effective COVID‐19 therapies?
title_sort can artificial intelligence identify effective covid‐19 therapies?
topic News & Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361072/
https://www.ncbi.nlm.nih.gov/pubmed/32569446
http://dx.doi.org/10.15252/emmm.202012817
work_keys_str_mv AT schultzmichaelb canartificialintelligenceidentifyeffectivecovid19therapies
AT veradaniel canartificialintelligenceidentifyeffectivecovid19therapies
AT sinclairdavida canartificialintelligenceidentifyeffectivecovid19therapies

Ejemplares similares